SG11202012595PA - Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain - Google Patents
Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtainInfo
- Publication number
- SG11202012595PA SG11202012595PA SG11202012595PA SG11202012595PA SG11202012595PA SG 11202012595P A SG11202012595P A SG 11202012595PA SG 11202012595P A SG11202012595P A SG 11202012595PA SG 11202012595P A SG11202012595P A SG 11202012595PA SG 11202012595P A SG11202012595P A SG 11202012595PA
- Authority
- SG
- Singapore
- Prior art keywords
- propenone
- ylamino
- pyrimidin
- piperidin
- phenoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862686797P | 2018-06-19 | 2018-06-19 | |
| PCT/EP2019/065815 WO2019243223A1 (fr) | 2018-06-19 | 2019-06-17 | Nouvelles formes cristallines de 1-(4-{[6-amino-5-(4-phénoxy-phényle)pyrimidin-4-ylamino]-méthyl}-4-fluoro-pipéridin-1-yl)-propénone, formes salines de celle-ci, et procédés d'obtention |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012595PA true SG11202012595PA (en) | 2021-01-28 |
Family
ID=67003464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012595PA SG11202012595PA (en) | 2018-06-19 | 2019-06-17 | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11878967B2 (fr) |
| EP (1) | EP3810590A1 (fr) |
| JP (1) | JP2021527685A (fr) |
| KR (1) | KR20210022674A (fr) |
| CN (1) | CN112313214A (fr) |
| AU (1) | AU2019289628B2 (fr) |
| BR (1) | BR112020025881A2 (fr) |
| CA (1) | CA3104191A1 (fr) |
| CL (1) | CL2020003272A1 (fr) |
| IL (1) | IL279485A (fr) |
| MX (1) | MX2020013321A (fr) |
| SG (1) | SG11202012595PA (fr) |
| WO (1) | WO2019243223A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220130151A (ko) * | 2020-01-08 | 2022-09-26 | 텔리오스 파마, 인크. | 비장비대의 치료 방법 |
| US20240024314A1 (en) * | 2020-01-08 | 2024-01-25 | Telios Pharma, Inc. | Methods of Treating Splenomegaly |
| JP2023528952A (ja) | 2020-06-10 | 2023-07-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 操縦可能アンテナならびに操縦可能アンテナを加熱および／または焼戻す方法 |
| CN117986236A (zh) * | 2022-11-07 | 2024-05-07 | 天津征程医药科技有限公司 | 氘代的嘧啶衍生物以及包含该化合物的药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA027584B1 (ru) * | 2011-06-10 | 2017-08-31 | Мерк Патент Гмбх | Композиции и способы получения пиримидиновых и пиридиновых соединений с btk ингибирующей активностью |
| KR20190040370A (ko) | 2012-06-04 | 2019-04-17 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| CN103694241A (zh) | 2013-11-27 | 2014-04-02 | 苏州晶云药物科技有限公司 | Pci-32765的新晶型a及其制备方法 |
| CN107530345A (zh) * | 2015-03-03 | 2018-01-02 | 雷迪博士实验室有限公司 | 依鲁替尼的多晶型物 |
| JP6705833B2 (ja) * | 2015-04-02 | 2020-06-03 | ラティオファルム ゲー・エム・ベー・ハー | イブルチニブとカルボン酸との共結晶 |
| PL3371165T3 (pl) | 2015-11-04 | 2022-05-02 | Merck Patent Gmbh | Inhibitor btk do zastosowania w terapii rakowej |
| RS64908B1 (sr) * | 2015-11-17 | 2023-12-29 | Merck Patent Gmbh | Metode za lečenje multiple skleroze korišćenjem jedinjenja pirimidina i piridina sa inhibitornom aktivnošću btk |
| US10464923B2 (en) * | 2017-02-27 | 2019-11-05 | Merck Patent Gmbh | Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone |
-
2019
- 2019-06-17 WO PCT/EP2019/065815 patent/WO2019243223A1/fr unknown
- 2019-06-17 BR BR112020025881-4A patent/BR112020025881A2/pt unknown
- 2019-06-17 KR KR1020217001602A patent/KR20210022674A/ko unknown
- 2019-06-17 CN CN201980041020.4A patent/CN112313214A/zh active Pending
- 2019-06-17 MX MX2020013321A patent/MX2020013321A/es unknown
- 2019-06-17 EP EP19732937.8A patent/EP3810590A1/fr active Pending
- 2019-06-17 US US17/252,804 patent/US11878967B2/en active Active
- 2019-06-17 AU AU2019289628A patent/AU2019289628B2/en active Active
- 2019-06-17 CA CA3104191A patent/CA3104191A1/fr active Pending
- 2019-06-17 JP JP2020570863A patent/JP2021527685A/ja active Pending
- 2019-06-17 SG SG11202012595PA patent/SG11202012595PA/en unknown
-
2020
- 2020-12-16 IL IL279485A patent/IL279485A/en unknown
- 2020-12-17 CL CL2020003272A patent/CL2020003272A1/es unknown
-
2023
- 2023-12-07 US US18/532,710 patent/US20240132472A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11878967B2 (en) | 2024-01-23 |
| CA3104191A1 (fr) | 2019-12-26 |
| US20210261525A1 (en) | 2021-08-26 |
| JP2021527685A (ja) | 2021-10-14 |
| CN112313214A (zh) | 2021-02-02 |
| WO2019243223A1 (fr) | 2019-12-26 |
| CL2020003272A1 (es) | 2021-05-07 |
| IL279485A (en) | 2021-01-31 |
| MX2020013321A (es) | 2021-02-22 |
| AU2019289628A1 (en) | 2021-02-04 |
| KR20210022674A (ko) | 2021-03-03 |
| US20240132472A1 (en) | 2024-04-25 |
| EP3810590A1 (fr) | 2021-04-28 |
| BR112020025881A2 (pt) | 2021-03-23 |
| AU2019289628B2 (en) | 2024-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906361B (en) | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone | |
| SG11202012595PA (en) | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain | |
| IL266214B (en) | 5,4,2-tri-converted 4,2,1-triazolones used as dhodh inhibitors | |
| MX2017014108A (es) | Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-ilox i) metilo) ciclopropanamina, su forma cristalina y sus sales. | |
| WO2016105525A3 (fr) | Nouvelles pyrimidines en tant qu'inhibiteurs d'egfr et procédés de traitement de troubles | |
| MY178552A (en) | Heterocyclic amides as kinase inhibitors | |
| PL3464276T3 (pl) | Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu | |
| SG11201707899SA (en) | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same | |
| MX2021013970A (es) | Formas cristalinas de n-[4-(clorodifluorometoxi)fenil]-6-[(3r)-3-h idroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida. | |
| IL273974B1 (en) | Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors, salts thereof and method for their synthesis | |
| HK1204788A1 (en) | Method of producing 4-[5-(pyridin-4-yl)-1h-1,2,4-triazole-3- yl]pyridin-2-carbonitrile, and intermediary thereof 4-[5-(-4-)-1h-124--3-]-2- | |
| HK1245268A1 (zh) | 含氮雜環化合物的製造方法及其中間體 | |
| MX2017011330A (es) | Proceso quimico para preparar derivados de pirimidina y sus intermediarios. | |
| IL257463A (en) | Novel crystalline form of 3-(6-(1-(2, 2-difluorobenzo [d] [1, 3] dioxole -5-yl) cyclopropanecarboxamido)-3-methylpyridine-2-yl) benzoic acid and process of preparation thereof | |
| ZA201907272B (en) | N-(4-pyridyl)nicotinamide compound or salt thereof | |
| NZ742785A (en) | Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine | |
| GB2534913B (en) | System, method, and program for storing and controlling access to data representing personal behaviour | |
| FR3019715B1 (fr) | Composition fertilisante et biostimulante contenant des fructo-oligosaccharides, procede d'application et utilisations | |
| IL253717A0 (en) | Crystalline form of s-(4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl)6a,9a-difluoro-17a,-(furan-2-yl)carbonyloxy-11b-hydroxy-16a-methy1-3 -oxoandrosta-1,4-diene-17b-carbothioate | |
| EP3345898A4 (fr) | Cristaux d'acide 5-cyclopropyl-2-((1-(3-fluorobenzyl)-1h-indol-5-yl)amino)nicotinique | |
| EA201991977A1 (ru) | Новые кристаллические формы 1-(4-{[6-амино-5-(4-феноксифенил)пиримидин-4-иламино]метил}пиперидин-1-ил)пропенона |